7 Oct 2016 07:00
EKF Diagnostics Holdings plc
("EKF", the "Company")
Trading update
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that trading in Q3 of the current financial year was materially higher than budget and at a run-rate in excess of market forecasts. As a result the Company is now confident of achieving revenues and adjusted EBITDA for 2016 which will exceed the high end of current market forecasts.
In addition, the Company announces that cash generation during the quarter has been strong and its net debt position has improved considerably. While the Company plans to continue investing during Q4 and early 2017 in capital expenditure to increase consumables capacity in Germany and to replace equipment in the USA, it now expects to be cash positive within the next 12 months.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
Christopher Mills, Non-Executive Chairman | Tel: 029 2071 0570 |
Julian Baines, CEO | |
Richard Evans, FD & COO | |
Panmure Gordon (UK) Limited (NOMAD & Joint Broker) | Tel: 020 7886 2500 |
Freddy Crossley / Peter Steel (Corporate Finance) | |
N+1 Singer (Joint Broker) | Tel: 020 7496 3000 |
Alex Price / Alex Laughton-Scott | |
Walbrook PR Limited | Tel: 020 7933 8780 or ekf@walbrookpr.com |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 |
Ekf Diagnostics (EKF)